Released Nov 5, 2026, after the close
10-Q filed Nov 5, 2026, 36 days after period end · 0001104659-26-123322
In September 2026, the Company reported best-in-disease topline results from the Phase 3 EMBARQ-CSU1 and -CSU2 studies of barzolvolimab in patients with CSU whose symptoms are inadequately controlled by H1-antihistamines.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | — | $3.19M | $1.52M |
| Net Income | -$75.56M | -$67.04M | -$42.12M |
Celldex Therapeutics, Inc. · CIK 744218 · Engraved from SEC EDGAR
| — |
| EPS Diluted | -$0.96 | -$1.01 | -$0.64 | -$0.81 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Celldex reported a net loss of $75.6 million, or ($0.96) per share, for the third quarter of 2026, compared to a net loss of $67.0 million, or ($1.01) per share, for the third quarter of 2025.¶2
Research and development expenses were $67.4 million in the third quarter of 2026, compared to $62.9 million in the third quarter of 2025, driven by barzolvolimab clinical trial and contract manufacturing expense.¶3
Cash, cash equivalents and marketable securities were $650.3 million at September 30, 2026, and the Company believes this amount funds planned operations through 2028.¶4¶5
In the Phase 3 EMBARQ-CSU studies, treatment will continue to 52 weeks, and the Company anticipates a BLA submission for barzolvolimab in CSU in 2027.¶1¶6